Hikal Limited — Important, 26-09-2025: Updates
26-09-2025 | 03:54 pm
26-09-2025 | 03:54 pm
Hikal's Jigani unit received a US FDA Warning Letter for inadequate complaint investigations and vendor management. Classified as "Official Action Intended," this could delay H1 revenues into H2. Hikal has responded with corrective actions and is closely engaging with US FDA for resolution.
No comments yet. Be the first to comment!
